Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05722171
Other study ID # PG-p002-015
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date December 27, 2022
Est. completion date December 27, 2024

Study information

Verified date January 2023
Source PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Contact Heng Mei, Doctor
Phone +86-13886160811
Email mayheng@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-arm, open-label, dose-escalation study to explore the safety, efficacy, and cytodynamic characteristics of the drug, and to initially observe the efficacy of the drug in subjects with relapsed/refractory B7-H3-positive acute myeloid cell line leukemia.


Description:

Eligible subjects will receive 1.0×10^8 CAR gdT, 2.0×10^8 CAR gdT, 4.0×10^8 CAR gdT, or additional doses may be added at the discretion of investigator and sponsor.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date December 27, 2024
Est. primary completion date December 27, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - (1) Age= 18 years old, gender is not limited; - (2) expected survival time= 3 months; - (3) ECOG score 0-1 points; - (4) Acute myeloid leukemia was clearly diagnosed during screening, and tumor cells were positive for B7-H3 expression; - (5) Subjects with relapsed/refractory acute myeloid leukemia who have failed standard treatment or lack effective treatment methods. - (6) Coagulation function, liver and kidney function, cardiopulmonary function meet requirements. - (7) Be able to understand the trial and have signed the informed consent form. Exclusion Criteria: - (1) Malignant tumors other than acute myeloid leukemia within 5 years before screening; - (2) Those who test positive for virus and syphilis; - (3) Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification= grade III), severe arrhythmia; - (4) Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment; - (5) Active infection or uncontrollable infection requiring systemic treatment within 7 days prior to screening; - (6) pregnant or lactating women, female subjects who planned to become pregnant within 2 years after cell reinfusion or male subjects whose partners planned to become pregnant within 2 years after their cell reinfusion; - (7) Subjects who were receiving systemic steroid therapy within 7 days prior to the year or who were judged by the investigator to require long-term systemic steroid therapy during treatment (other than inhalation or topical use); - (8) Have participated in other clinical studies within 1 month before screening; - (9) There was evidence of central nervous system invasion during subject screening, such as tumor cells detected in cerebrospinal fluid or imaging showing central infiltration; - (10) Those who have graft-versus-host response and need to use immunosuppressants; - (11) Those with a history of epilepsy or other central nervous system diseases; - (12) Patients with primary immunodeficiency diseases; - (13) situations that other investigators consider unsuitable for enrollment.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
gdT cell injection targeting B7-H3 chimeric antigen receptor
The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1E8, 2E8 and 4E8 CAR-gdT groups in order of sequence. And the subjects will be administered once.

Locations

Country Name City State
China PersonGen Anke Cellular Therapeutice Co., Ltd. Hefei Anhui

Sponsors (1)

Lead Sponsor Collaborator
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of the safety after UTAA06 injection treatment (Safety) Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. About 2 years
Secondary To evaluate anti-tumor activity (overall survival) Defined as the time from start of UTAA06 UTAA06 infusion therapy to death (due to any cause) About 2 years
Secondary To evaluate anti-tumor activity (duration of response) Defined as the time from the first tumor assessment of CR or PR, CR or CRi to the first assessment of disease recurrence or progression or death (due to any cause). About 2 years
Secondary To evaluate anti-tumor activity (progression free survival) Defined as the time from the start of UTAA06 infusion therapy to the first disease progression or recurrence or death from any cause. About 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05731219 - UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT05061147 - A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Phase 1/Phase 2
Not yet recruiting NCT05548088 - LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Terminated NCT03504410 - Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML Phase 3
Enrolling by invitation NCT05332054 - Long-Term Follow-up Study
Withdrawn NCT03904069 - Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML Phase 1
Completed NCT05518357 - LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT03190278 - Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Completed NCT02665143 - A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia Phase 2
Completed NCT03886831 - A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies Phase 1
Completed NCT03318016 - Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT06084819 - Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Phase 2
No longer available NCT05627466 - US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia